about
Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomesMeta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressantsEfficacy and tolerability of second-generation antidepressants in social anxiety disorderConfounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART.Expert panel assessment of acute liver injury identification in observational data.Developing an expert panel process to refine health outcome definitions in observational data.The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis.Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials.Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review.Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis.Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data.Prescription refill records as a screening tool to identify antidepressant non-adherence.Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record.Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.A simple and valid tool distinguished efficacy from effectiveness studies.The study of direct-to-consumer advertising for prescription drugs.Serious adverse events with infliximab: analysis of spontaneously reported adverse events.Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence.Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis.Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care.Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose.Enhancing Quality in Psychiatry with Psychiatrists (EQUIPP)--results from a pilot study.Inadequate reporting of trials compromises the applicability of systematic reviews.The intersection of patient complexity, prescriber continuity and acute care utilization.Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment.How should primary care doctors select which antidepressants to administer?Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis.How well do various health outcome definitions identify appropriate cases in observational studies?Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising.Patterns of psychiatric emergency department utilization among community-dwelling Medicare beneficiaries under 65.Antidepressant Medication Use and Its Association With Cardiovascular Disease and All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.Repeat medication errors in nursing homes: Contributing factors and their association with patient harm.Achieving Adherence After First-Line Antihypertensive Treatment: Should Fixed-Dose Combinations Receive Priority?Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.
P50
Q22306079-7762AB72-461E-49CD-9D93-7454F4289E4FQ24624760-4BCE7A43-B09F-414C-A9DE-7EF138DFBDF8Q24656009-48203E8D-4712-42FB-9E7F-82ABE2D768BCQ30590458-5952A57B-44D4-41B5-AB2B-630E99D52974Q30642748-6C490D35-D956-447B-A249-69A86C358103Q30648659-6251CB8D-73C9-49E4-A44C-27625F95B39AQ30886413-73A1CB22-3BF4-4EE4-86AE-638B95789FEFQ33212249-313BAA66-F3F7-40AC-8A07-CAF85D51F28EQ33274853-29F61EC7-F229-4320-870C-2AAB2B5CD975Q33365152-36FCD9AE-8045-4AB7-AFE0-19364834803BQ33413352-5ADDC151-5436-4F75-9FD0-04A266692C7AQ34254323-F4E80792-8EA3-4BF3-A748-F8741C912093Q34424402-1A879595-8A2F-4D8B-95E3-3159CBAAAEF1Q34529168-E9BD76EC-6959-4940-86FA-BC3F1BE04449Q34672989-F925F92E-36DE-4A69-82E9-B4DA94CA6EA9Q34833895-A3096110-FF25-469E-8248-3744941853C2Q35066804-3331114E-AECF-4BF4-AA49-D49B0D71BF49Q35162633-43D76027-DBE9-4BFD-8473-A0A6DD8ED6E8Q35549106-1A3B2828-A559-4043-B647-AC93B0DABF5BQ36412644-F11CB7E2-22B0-4954-837B-D9ED8A2EAABFQ36596046-48AFB375-BE95-4CEF-92C2-4B9A928BE499Q36670152-7DA5134A-C617-4ADC-9A0A-DED248D0731CQ36811847-49D36911-64EA-4E82-B9CA-E89E1089F0ECQ36849754-95A0C982-A87F-4717-80C9-18A36AD31EC1Q37151683-052BA1EC-590C-4101-9BF8-C30756B04547Q37292588-651093B1-B33F-424F-98C8-7960783E9E10Q37367742-634CD995-0D6C-4CB6-AF9A-AA473219D32FQ37394732-015B1183-2F0B-47C0-BBAA-AC86AAF83862Q37556683-93BE67CA-1A41-462F-B9C8-F8B3EDAE02CEQ37663051-4E6267DE-2467-4BA8-8D7E-687E67A78A6AQ37665729-5CDDDB56-83F5-4C14-8DFA-7F22E43853A5Q38014710-DF89FEC4-1B57-4A8E-8599-0DD337DA9CDDQ38054991-B1D583A6-416F-45AA-B053-B05BECA8D6FBQ38156065-404E65D4-8AD4-4E9F-93CC-F4AA0175B60CQ38470934-FEE38A20-A1BC-49D0-84DC-5FA8C55986F3Q38626251-0F071CE5-FFA9-4DD9-BBC1-80F6999415F0Q38702437-2CA1854F-EE6E-4408-A7FB-D0D0C776E3F7Q39857924-4535D895-0957-48EC-BF45-42CBEBA08A9BQ39967146-F945C8EA-0996-4F54-ABFC-F465F6FF8765Q40052079-AD0799E0-FF17-4D63-8177-8BF3CEFAB1CB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Richard A Hansen
@nl
Richard A Hansen
@sl
Richard A. Hansen
@en
Richard A. Hansen
@es
type
label
Richard A Hansen
@nl
Richard A Hansen
@sl
Richard A. Hansen
@en
Richard A. Hansen
@es
prefLabel
Richard A Hansen
@nl
Richard A Hansen
@sl
Richard A. Hansen
@en
Richard A. Hansen
@es
P106
P1153
8083291100
P21
P31
P496
0000-0002-4578-6698